Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy (ATHETOID_CD)
This study has been completed.
Seoul National University Hospital
Information provided by (Responsible Party):
Keewon Kim, Seoul National University Hospital
First received: May 13, 2013
Last updated: August 19, 2017
Last verified: August 2017
This study aimed to compare the efficacy and safety of Meditoxin® injection for cervical dystonia in adults with cerebral palsy. It is a placebo controlled, Cross-over, Double blind, Randomized, Clinical trial.
|Study Design:||Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||A Placebo Controlled, Cross-over, Double Blind, Randomized, Clinical Trial to Compare the Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Keewon Kim, Seoul National University Hospital:
Primary Outcome Measures:
- Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) [ Time Frame: 0, 16, 32 weeks ]Change of Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) from baseline TWSTRS at 0 week.
Secondary Outcome Measures:
- Pain in numerical rating scale (NRS) [ Time Frame: Every 4 weeks, up to 32 weeks ]Pain in numerical rating scale (NRS)
- Japanese Orthopaedic Association (JOA) score [ Time Frame: Every 4 weeks, up to 32 weeks ]Change of Japanese Orthopaedic Association (JOA) score from baseline Japanese Orthopaedic Association (JOA) score at 0 week.
- Goal attainment scale [ Time Frame: 4, 12, 20, 28 weeks ]Goal attainment scale of subjective improvement from the baseline status at 0 and 16 weeks.
Other Outcome Measures:
- Adverse effect [ Time Frame: Every 4 weeks, up to 32 weeks ]vital sign, adverse effect
- computed tomography (CT) [ Time Frame: 0, 32 weeks ]Change of cervical spine computed tomography (CT) from baseline CT at 0 week.
- videofluoroscopic swallowing study (VFSS) [ Time Frame: 0, 12, 28 weeks ]Change of videofluoroscopic swallowing study (VFSS) from baseline VFSS at 0 week.
- Blood/Urine laboratory tests [ Time Frame: 0, 16, 32 weeks ]
- Hemoglobin, Hematocrit, RBC, WBC, WBC different cell count, Platelet
- Alkaline phosphatase, BUN, Creatinine, SGPT(ALT), SGOT(AST), Albumin, Total protein, Total bilirubin, Uric acid, Glucose, Cholesterol, LDH, Na, Ca, K, Cl
- Urine pH, Protein, Glucose, Bilirubin, Blood, WBC
|Study Start Date:||June 2013|
|Study Completion Date:||June 2017|
|Primary Completion Date:||March 2017 (Final data collection date for primary outcome measure)|
Active Comparator: Treatment-Placebo Group
Treatment on 0 day Placebo at 5th week
Active Comparator: Placebo-Treatment Group
Placebo on 0 day Treatment at 5th week
|Drug: Normal saline|
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
No Contacts or Locations Provided
No Contacts or Locations Provided